Cleared Is Not Validated: The Evidence Gap Behind FDA's AI Device Count
FDA's public summaries for AI-enabled devices were built to demonstrate fairness, but their format makes that fairness nearly impossible to verify.
Find here all our blog posts tagged with: medical devices.
The Real AI Device Risk Is Where FDA Doesn't Look Closely
Most AI-enabled devices clear FDA through the least rigorous pathway or avoid device classification entirely, leaving agentic AI's failure modes unexamined.
FDA Is Assembling the Machinery Before It Finishes the Rule
FDA's device review architecture and new leadership roles point toward trial-side AI scrutiny, though the timeline and scope remain genuinely unsettled.
The Oversight Question Autonomous Diagnostic AI Hasn't Answered
FDA's latest device clearances shift AI from assistive to autonomous interpretation, and compliance teams still lack a shared standard for human oversight.
Two New Fast Lanes for AI Devices, No New Evidence Standard
EU and FDA are both building faster pathways for AI medical devices, but neither has defined what evidence should earn a device the fast lane.
The EU AI Act Reprieve Is a Timing Bet, Not a Pause
Digital Omnibus alignment gives AI-enabled medical devices breathing room on paper, but MDR/IVDR certification obligations have not moved and neither has the underlying risk.
Europe's New Fast Lane for Breakthrough AI Devices Comes With No Governance Shortcut
The EU's new Breakthrough Devices framework under MDR/IVDR speeds review timelines but leaves AI governance obligations fully intact.
FDA's Postmarket AI Machinery Is Still Under Construction
Recent FDA moves on AI-enabled devices signal a postmarket framework taking shape, but the agency's own uncertainty argues against treating early engagement as a settled strategy.
The Readiness Gap Behind FDA's 1,000 AI Devices
FDA's large base of authorized AI-enabled devices masks a readiness gap that generative and agentic systems will expose immediately.
FDA's AI Perimeter Is Widening and Narrowing at the Same Time
FDA is loosening wellness device classification while tightening AI change control mechanics, and the gap between the two is where compliance risk now sits.
The Real Gap Isn't Evidence. It's Framework Fit.
AI medical device clearances are outpacing the regulatory architecture meant to govern them, and hospitals are deploying generative AI ahead of any classification at all.
FDA Clearance Is Not the Evidence Trail
FDA-authorized AI devices are outpacing the evidence behind their safety and equity claims, leaving health systems to build the diligence layer themselves.
Static Categories, Adaptive Systems: The Real Fault Line in AI Device Review
FDA and EU sandbox pilots for agentic AI are one symptom of a broader breakdown in static regulatory categories, and buyers should treat both the hype and the early-engagement tradeoffs with equal scrutiny.
FDA's GenAI Framework Is Still a Draft of a Draft. That's the Opportunity.
FDA's two-axis risk framework for generative AI medical devices is not policy yet, and the October 19 comment window is the cheapest chance to shape it before it hardens.
The Comment Window That Will Define GenAI Medical Devices
FDA's open docket on generative AI medical devices is the narrow window life sciences leaders have to shape binding rules before they harden.
FDA's GenAI Pilot Is Ahead of Its Own Guardrails
FDA's provisional pathway for generative AI devices exposes a verification gap that output benchmarks and existing life cycle rules were not built to close.
The FDA's Open Docket Is the Real Deadline
FDA's move toward assessing generative AI devices like clinicians raises real feasibility questions, but sponsors who wait for guidance will lose the argument.
FDA's New Deputy Commissioner Post Is the Real AI Signal
HHS is creating a dedicated technology leadership role at FDA, and that appointment will shape AI device oversight more than any single guidance document.
What FDA's Tempo Pilot Actually Asks Compliance Leaders to Decide
FDA's reported Tempo pilot lets generative AI devices reach patients ahead of authorization, and the public record on how is thinner than the headline suggests.
FDA's Three-Part Test for Agentic Devices
FDA's generative AI discussion paper outlines a safety, proficiency, and generalizability framework that will shape validation evidence long before formal guidance arrives.
The Generative AI Gap in FDA's Device Playbook
FDA has cleared over 1,000 AI-enabled devices, but generative AI features still lack a defined regulatory pathway, forcing sponsors to choose their architecture carefully.
Three Regulators, Three Clocks, One AI-Enabled Device
The EU, US, and China are each running statute ahead of certification infrastructure for AI-enabled medical devices, and manufacturers need one documentation architecture, not three.
The PCCP Is the Real Clearance
FDA's predetermined change control plans, not the original device clearance, now define how far an AI-enabled medical device can drift without new review.
FDA's RWE Guidance Widens the Door. It Doesn't Lower the Bar.
FDA's final real-world evidence guidance broadens what device sponsors can submit, but the decision that matters is whether data pipelines can meet the traceability bar the broader door implies.
The Platform Risk Hiding in Serial Clearances
Tempus AI's third ECG-based FDA clearance shows how one platform can accrete indications faster than buyers can verify its cumulative risk profile.
